Percutaneous Endoscopic Gastrostomy Tube Placement in Patients with Head and Neck Cancer Treated with Radiotherapy.
PEG placement
body mass index
head and neck cancer
radiotherapy
toxicity
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
06
2019
accepted:
02
12
2019
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
The primary aim of our study was to evaluate percutaneous endoscopic gastrostomy (PEG) tube placement depending on body weight and body mass index in patients undergoing radiotherapy (RT) for head and neck cancer (HNC). A secondary aim was to evaluate the course of weight change following PEG placement. We retrospectively reviewed the medical records of 186 patients with HNC undergoing radiotherapy (RT) or chemoradiotherapy (CRT) at our institution between January 2010 and August 2017. Initial weight and nutritional intake were analyzed prior to RT initiation and then followed throughout treatment until completion. Based on these data, the indication of PEG placement was determined. Medical records were also reviewed to analyze PEG-related acute toxicities. A total of 186 patients met inclusion criteria. Patients were most commonly male (n=123, 66.1%) with squamous cell carcinoma (n=164, 88.2%). Patients who had dysphagia prior to treatment initiation as well as patients with a BMI <18.5 kg/m Underweight patients and those with preexisting dysphagia should be closely screened during RT for weight loss and decreased oral intake. For weight loss greater than 4.5% during the treatment of HNC, early PEG-tube placement should be considered. Further prospective studies are needed to confirm these findings, and delineate a scoring system for timing of PEG use (prophylactic vs reactive) as well as assess the quality of life in patients with HNC who receive PEG placement.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
The primary aim of our study was to evaluate percutaneous endoscopic gastrostomy (PEG) tube placement depending on body weight and body mass index in patients undergoing radiotherapy (RT) for head and neck cancer (HNC). A secondary aim was to evaluate the course of weight change following PEG placement.
METHODS
METHODS
We retrospectively reviewed the medical records of 186 patients with HNC undergoing radiotherapy (RT) or chemoradiotherapy (CRT) at our institution between January 2010 and August 2017. Initial weight and nutritional intake were analyzed prior to RT initiation and then followed throughout treatment until completion. Based on these data, the indication of PEG placement was determined. Medical records were also reviewed to analyze PEG-related acute toxicities.
RESULTS
RESULTS
A total of 186 patients met inclusion criteria. Patients were most commonly male (n=123, 66.1%) with squamous cell carcinoma (n=164, 88.2%). Patients who had dysphagia prior to treatment initiation as well as patients with a BMI <18.5 kg/m
CONCLUSION
CONCLUSIONS
Underweight patients and those with preexisting dysphagia should be closely screened during RT for weight loss and decreased oral intake. For weight loss greater than 4.5% during the treatment of HNC, early PEG-tube placement should be considered. Further prospective studies are needed to confirm these findings, and delineate a scoring system for timing of PEG use (prophylactic vs reactive) as well as assess the quality of life in patients with HNC who receive PEG placement.
Identifiants
pubmed: 32021429
doi: 10.2147/CMAR.S218432
pii: 218432
pmc: PMC6955619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
127-136Informations de copyright
© 2020 Lang et al.
Déclaration de conflit d'intérêts
Dr Sebastian Adeberg report personal fees from Merck Serono GmbH, other from Novocure, personal fees from Accuray International Sarl, outside the submitted work. Prof. Dr. Jürgen Debus report grants from Merck Serono, grants from Accuray, grants, non-financial support from Siemens Healthineers, non-financial support from Research Labs, outside the submitted work. The authors report no other conflict of interest in this work.
Références
Clin Adv Hematol Oncol. 2005 May;3(5):373-82
pubmed: 16167011
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Am J Med Sci. 2008 Sep;336(3):291-2
pubmed: 18794629
Nutr Clin Pract. 1996 Aug;11(4):157-69
pubmed: 9070017
Dysphagia. 2016 Feb;31(1):84-9
pubmed: 26487063
World J Gastroenterol. 2011 Feb 28;17(8):1004-8
pubmed: 21448351
Gastroenterology. 1987 Jul;93(1):48-52
pubmed: 3108063
Head Neck. 2014 Aug;36(8):1155-61
pubmed: 23852670
Support Care Cancer. 2000 Sep;8(5):410-3
pubmed: 10975691
Nutrients. 2015 Jan 05;7(1):265-76
pubmed: 25569622
Curr Opin Otolaryngol Head Neck Surg. 2016 Jun;24(3):208-14
pubmed: 27054623
Arch Otolaryngol Head Neck Surg. 1998 Aug;124(8):871-5
pubmed: 9708712
Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):178-83
pubmed: 18283161
Curr Opin Otolaryngol Head Neck Surg. 2015 Apr;23(2):162-70
pubmed: 25692626
Nutr Clin Pract. 1997 Feb;12(1 Suppl):S34-7
pubmed: 9077229
Dysphagia. 2010 Jun;25(2):139-52
pubmed: 19711127
JAMA. 1998 Jun 24;279(24):1973-6
pubmed: 9643861
Otolaryngol Head Neck Surg. 2014 Mar;150(3):407-12
pubmed: 24381015
Ann Oncol. 2012 Oct;23 Suppl 7:vii83-5
pubmed: 22997460
Int J Clin Oncol. 2018 Dec;23(6):1023-1028
pubmed: 30121869
Oral Oncol. 2012 May;48(5):434-40
pubmed: 22209648
Ann Oncol. 2010 May;21 Suppl 5:v187-9
pubmed: 20555078
Int J Radiat Oncol Biol Phys. 2010 Nov 15;78(4):1026-32
pubmed: 20231073
Clin Nutr. 2017 Feb;36(1):11-48
pubmed: 27637832
Otolaryngol Head Neck Surg. 1999 Apr;120(4):479-82
pubmed: 10187937
Acta Otolaryngol. 2014 Oct;134(10):1079-85
pubmed: 25131392
Head Neck. 2012 Jan;34(1):1-9
pubmed: 21374756
J Laryngol Otol. 2006 Jun;120(6):463-6
pubmed: 16772054
Cancer. 2012 Dec 15;118(24):6072-8
pubmed: 22707358
Int J Radiat Oncol Biol Phys. 2011 Mar 1;79(3):763-9
pubmed: 20510546
Dysphagia. 2012 Jun;27(2):251-9
pubmed: 21850606
Nutr Clin Pract. 2007 Feb;22(1):68-73
pubmed: 17242458
JPEN J Parenter Enteral Nutr. 2009 Jul-Aug;33(4):404-10
pubmed: 19520799